Pembrolizumab as first-line treatment for metastatic uveal melanoma

BACKGROUND: No standard treatment has been defined for metastatic uveal melanoma (mUM). Although clinical trials testing Nivolumab/Pembrolizumab for cutaneous melanoma did not include mUM, anti PD-1 agents are commonly used for this disease. PATIENTS AND METHODS: In this prospective observational co...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Ernesto, Pagliara, Monica Maria, Orteschi, Daniela, Dosa, Tommaso, Sammarco, Maria Grazia, Caputo, Carmela Grazia, Petrone, Gianluigi, Rindi, Guido, Zollino, Marcella, Blasi, Maria Antonietta, Cassano, Alessandra, Bria, Emilio, Tortora, Giampaolo, Schinzari, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584707/
https://www.ncbi.nlm.nih.gov/pubmed/31175402
http://dx.doi.org/10.1007/s00262-019-02352-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584707/
https://www.ncbi.nlm.nih.gov/pubmed/31175402
http://dx.doi.org/10.1007/s00262-019-02352-6

Ejemplares similares